Aspira Pathlab Diagnostics Ltd vs Fortis Malar Hospitals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Aspira Pathlab & Diagnostics Ltd is ₹ 143.34 as of 29 Sep 10:20 . The P/E Ratio of Aspira Pathlab & Diagnostics Ltd changed from 43.3 on March 2025 to 0 on March 2026 . This represents a CAGR of -100.00% over 2 yearsThe P/E Ratio of Fortis Malar Hospitals Ltd changed from 1.9 on March 2024 to 18.9 on March 2026 . This represents a CAGR of 115.06% over 3 years The Market Cap of Aspira Pathlab & Diagnostics Ltd changed from ₹ 31.91 crore on March 2024 to ₹ 0 crore on March 2026 . This represents a CAGR of -100.00% over 3 yearsThe Market Cap of Fortis Malar Hospitals Ltd changed from ₹ 103.92 crore on March 2021 to ₹ 78.13 crore on March 2026 . This represents a CAGR of -4.64% over 6 years The revenue of Aspira Pathlab & Diagnostics Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Fortis Malar Hospitals Ltd for the Jun '26 is ₹ 0.54 crore as compare to the Mar '26 revenue of ₹ 0.66 crore. This represent the decline of -18.18% The ebitda of Aspira Pathlab & Diagnostics Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Fortis Malar Hospitals Ltd for the Jun '26 is ₹ 0.2 crore as compare to the Mar '26 ebitda of ₹ 0.11 crore. This represent the growth of 81.82% The net profit of Aspira Pathlab & Diagnostics Ltd changed from ₹ 0.05 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of -100.00% The net profit of Fortis Malar Hospitals Ltd changed from ₹ -0.06 crore to ₹ 0.15 crore over 9 quarters. This represents a CAGR of NaN% The Dividend Payout of Aspira Pathlab & Diagnostics Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Fortis Malar Hospitals Ltd changed from 168.63 % on March 2024 to 0 % on March 2026 . This represents a CAGR of -100.00% over 3 years .

About Aspira Pathlab & Diagnostics Ltd

Aspira Pathlab & Diagnostics Limited (ASDL) was incorporated in July, 1973.
ASDL is a leading pathology specialist, with Pan-India presence.
It offer pathology and diagnostic services to individual patients, hospitals, other healthcare providers, and businesses.
The Company, with a wider presence in Maharashtra India, enjoys a loyal customer base, that reflects on its strength as a brand, providing superior diagnostic testing and services. Presently, Company is engaged into the business of running, owning, managing and administering Diagnostics Centers.
Its principal activities consist of pathology investigation services, radiology investigation services and other related healthcare services at Diagnostic Centres in Mumbai. ASDL ideology is founded on technological supremacy, patient centric approach, and dependable diagnostic results.

About Fortis Malar Hospitals Ltd

Fortis Malar Hospital Limited, formerly known as Malar Hospital Limited was established on April 12, 1989 to set up, manage and operate a multi-specialty hospital.
Company is a subsidiary of Fortis Hospitals Limited and Fortis Healthcare Limited is the Intermediate Holding Company.
Later, the Company changed its name to 'Fortis Malar Hospital Limited' on December 21, 2010.
The Hospital building was owned by a fellow subsidiary, Fortis Health Management Limited (FHML) in early 2008. The hospital founded in 1989, has established itself as one of the largest corporate hospitals in Chennai, providing quality super specialty and multi-speciality healthcare services.
With a total bed-strength of 160, including 40 ICU/CCU/RTU beds, the hospital focuses on providing comprehensive medical care in the areas of Cardiology and Cardiac Surgery, Neuro Surgery, Gynaecology, Orthopedics, Gastroenterology, Neurology, Pediatrics, Diabetics, Nephrology and Internal Medicine All the above departments are fully became operational under phase I of the project.

FAQs for the comparison of Aspira Pathlab & Diagnostics Ltd and Fortis Malar Hospitals Ltd

Which company has a larger market capitalization, Aspira Pathlab & Diagnostics Ltd or Fortis Malar Hospitals Ltd?

Market cap of Aspira Pathlab & Diagnostics Ltd is 129 Cr while Market cap of Fortis Malar Hospitals Ltd is 75 Cr

What are the key factors driving the stock performance of Aspira Pathlab & Diagnostics Ltd and Fortis Malar Hospitals Ltd?

The stock performance of Aspira Pathlab & Diagnostics Ltd and Fortis Malar Hospitals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aspira Pathlab & Diagnostics Ltd and Fortis Malar Hospitals Ltd?

As of October 25, 2026, the Aspira Pathlab & Diagnostics Ltd stock price is INR ₹126.05. On the other hand, Fortis Malar Hospitals Ltd stock price is INR ₹40.21.

How do dividend payouts of Aspira Pathlab & Diagnostics Ltd and Fortis Malar Hospitals Ltd compare?

To compare the dividend payouts of Aspira Pathlab & Diagnostics Ltd and Fortis Malar Hospitals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.